Secondary intra-tumor acute hypoxic condition following anti-angiogenic RCC therapy-associated disruption in vasculature was proposed to promote alternative strategies to support angiogenesis (angiogenic switch) such as selection of tumor cell clones independent of VEGF due to multiple molecular and/or cellular mechanisms [255, 257]. This evidence concerns the gene VEGFA and renal cell carcinoma.